FDA approvals

news report

FDA Approves First Regulatory T-Cell Therapy for Stem-Cell Transplants

Tregzi improved one-year chronic GVHD-free survival to 78% in a randomized trial of 187 adults, compared with 38.4% after a standard transplant.

August 11, 2026, 5:27 a.m. CDT